YK11

 YK11 is a selective androgen  receptor modulator (SARM), which activates AR without the N/C  interaction. In this study, we further investigated the mechanism by  which YK11 induces myogenic differentiation of C2C12 cells. The  induction of key myogenic regulatory factors (MRFs), such as myogenic  differentiation factor (MyoD), myogenic factor 5 (Myf5) and myogenin,  was more significant in the presence of YK11 than in the presence of  DHT. YK11 treatment of C2C12 cells, but not DHT, induced the expression  of follistatin (Fst), and the YK11-mediated myogenic differentiation was  reversed by anti-Fst antibody. 

 Myogenic differentiation is in  reference to the products ability to block myostatin. Myostatin  inhibition has been a really popular movement since the ban of most  prohormones as it looks to be a relatively unexplored area for muscle  growth and fat loss. There are currently a lot of claims about mystatin  inhibition, but not so much factual data on these products. YK11 will  have similar affects to DHT (possibly more potent) without the negatives  of DHT. What this means is that the product will most likely be  suppressive and require a post cycle, but not cycle support. It also  won’t have androgenic side affects like hair loss, acne, etc. The  increase in follistatin caused byYK11 will act as an antagonist to  mystatin (it will block myostatin) as well as the anabolic growth  properties of YK11. 

  In direct comparison to to LGD-4033  as the reference for assay upon animal models of anabolism and  androgenicity, YK-11 demonstrated higher efficacy withing anabolic  parameters and lesser androgenicity at equivalent dosages.
 

It induces muscle cells to make more follistatin which is a strong  myostatin inhibitor. Myostatin (also known as growth differentiation  factor 8, is a myokine (protein) produced by muscle cells that acts on  muscle cells to inhibit myogenesis. Myogenesis is muscle cell growth and  differentiation. Research through the years show that when you block  myostatin, it allows for significantly more muscle mass. So in research  myostatin inhibitors are researched to find cures for muscle diseases.
 

We expect YK11 to be more potent than SARM LGD in terms of overall  growth and feel. At this time, we expect this to be the strongest SARM  on the market at a regular dosing. While suppression can occur, we  expect this product to have low androgenic properties and can be used by  both men and women. From our experience with SARMs, we find there are  less losses of on-cycle results than pro-hormones, although typically  not as potent. We do expect this product to have similar results as a  moderately dosed Halodrol, without the alpha-male/androgenic feelings  while on it. 

 Recommended maximum dose YK11 is  require dosages of 2.0-5.0mg b.i.d (twice a day) in males and 0.5mg-2mg b.i.d.(twice a day) in  females to achieve optimal effects in humans for the noted indications. 

 In 2011, Yuichiro Kanno of Toho University published the results of an  initial study on YK11, confirming that the rare compound was a SARM.  However, most people are now considering it to be what’s called a  Myostatin Inhibitor. 

 YK11 attaches itself to the AR (androgen receptor), and modulates  specific muscle receptors while being able to eliminate the traditional  effects of steroids.

Most SARMS have limited androgenic side effects, but also lesser anabolic effect when compared to testosterone.

However, that’s not the case with YK 11 according to the Biological and Pharmaceutical Bulletin in 2013. When Kanno used C2C12 muscle cells to test the effects of the SARM, it was found that the muscle cells produce more anabolic factors if exposed to 500 nmol (nanomoles) YK11 than if you expose the same muscle cells to 500 nmol DHT.

YK11 induces muscle cells to make even more follistatin than  DHT does (a strong myostatin inhibitor). By working through the  androgen receptor, YK 11 is able to product effects just as powerful as  testosterone.

YK11 shows a lot of promise as a very powerful muscle building SARM.  It’s one of the newer SARMs currently undergoing research, but it looks  incredibly promising.

As a myostatin inhibitor, it will also be amazing when combined with  other SARMs. The only downside as people have mentioned are the fact  that it’s never been done on human or animal trials at this point.

There’s still a lot to be learned, so our opinion on this SARM will change as more research develops.